Loading patent…
AssigneeMemorial Sloan Kettering Cancer Center
InventorsMarcel Van Den Brink, Robert Jenq, Jonathan U. Peled
Estimating the term…
The present invention relates to methods and compositions for reducing the risk of cancer relapse in a subject who has received cancer treatment. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria Streptococcus anginosus, Parvimonas micra, Acidaminococcus intestini, Eubacterium limosum, Clostridium glycyrrhizinilyticum, Desulfosporosinus lacus, Eubacterium biforme, Anaerofustis stercorihominis, Pseudoramibacter alactolyticus, Peptococcus niger, Armatimonas rosea, Saccharofermentans acetigenes, Finegoldia magna, Levyella massiliensis, Gallicola barnesae, Murdochiella asaccharolytica, and Eubacterium brachy are associated with a reduced risk of cancer relapse.
A method for reducing the risk of cancer relapse or increasing likelihood of survival from a cancer relapse in a subject, comprising administering, to a subject in need of such treatment, an effective amount of a pharmaceutical composition comprising one or more isolated bacteria, wherein the isolated bacteria comprise a 16S rDNA sequence that has between about 95 and 100% identity with a nucleic acid sequence described by SEQ ID NO:1, and further comprising a biocompatible pharmaceutical carrier;
Dependencies are inferred from the claim text.